Aducanumab in early Alzheimer’s disease: topline results from two phase 3 trials

Topline results from two phase 3 trials, presented at AAIC 2020, have provided insight into the efficacy of aducanumab in patients with early Alzheimer’s disease (AD).

Aducanumab is monoclonal antibody that targets aggregated forms of Aβ, including soluble oligomers and insoluble fibers.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.